Wall Street analyst estimates for Sarepta Therapeutics, Inc. (SRPT): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases.
Consensus price target
$21.60 (+14% vs price $18.99)
between $17.00 and $27.00
Closing price, Nov 4
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $1.8B | $1.8B – $1.9B | $3.08 | 11 |
| 2027E | $1.4B | $1.2B – $1.6B | $0.34 | 11 |
| 2028E | $1.3B | $853M – $1.6B | -$0.03 | 11 |
Figures in USD · consensus as of October 29, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 31 |
| Hold | 18 |
| Sell | 6 |
| Strong Sell | 0 |
| Total analysts | 55 |
| Avg rating (−2 sell to +2 buy) | 0.46 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-05 | $0.07 | ||
| 2026-08-05 | $-0.05 | $0.22 | -123.0% |
| 2026-05-06 | $3.16 | $0.98 | +223.8% |
| 2026-02-25 | $-3.58 | $-1.03 | -247.6% |
| 2025-11-03 | $-1.80 | $-0.73 | -147.6% |
| 2025-08-06 | $2.02 | $0.83 | +142.8% |
| 2025-05-06 | $-4.60 | $-0.87 | -428.7% |
| 2025-02-26 | $1.50 | $1.38 | +8.7% |
Valuation Ratios
| Price / Book | 1.30 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.4M | $154.6M | $301.0M | $380.8M | $540.1M | $701.9M | $933.0M | $1.24B | $1.90B | $2.20B |
| Cost of Revenue | $130,000 | $7.4M | $34.2M | $56.6M | $63.4M | $97.0M | $140.0M | $150.3M | $319.1M | $881.5M |
| Gross Profit | $5.3M | $147.2M | $266.8M | $324.2M | $476.7M | $604.8M | $793.0M | $1.09B | $1.58B | $1.32B |
| Research & Development | $188.3M | $166.7M | $401.8M | $560.9M | $722.3M | $771.2M | $877.1M | $877.4M | $804.5M | $1.52B |
| Selling, General & Admin | $83.7M | $122.7M | $207.8M | $284.8M | $317.9M | $282.7M | $451.4M | $481.9M | $557.9M | $478.9M |
| Operating Expenses | $272.0M | $290.4M | $610.5M | $1.03B | $1.04B | $1.06B | $1.33B | $1.36B | $1.36B | $1.97B |
| Operating Income | -$266.7M | -$171.6M | -$343.6M | -$705.6M | -$564.2M | -$459.7M | -$536.2M | -$267.8M | $218.1M | -$657.8M |
| EBITDA | -$261.1M | -$34.8M | -$316.7M | -$658.7M | -$453.4M | -$317.4M | -$594.9M | -$453.7M | $316.9M | -$648.0M |
| Interest Expense | $1.9M | $5.8M | $33.7M | $30.7M | $59.9M | $63.5M | $53.2M | $22.0M | $18.4M | $9.7M |
| Pre-tax Income | -$267.3M | -$48.6M | -$362.6M | -$713.9M | -$553.1M | -$418.9M | -$690.0M | -$520.1M | $260.8M | -$702.2M |
| Income Tax | 0 | $2.1M | -$692,000 | $1.2M | $1.1M | -$168,000 | $13.5M | $15.9M | $25.5M | $11.2M |
| Net Income | -$267.3M | -$50.7M | -$361.9M | -$715.1M | -$554.1M | -$418.8M | -$703.5M | -$536.0M | $235.2M | -$713.4M |
| EPS | -$5.49 | -$0.86 | -$5.46 | -$9.71 | -$7.11 | -$5.15 | -$8.03 | -$5.80 | $2.47 | -$7.13 |
| EPS (Diluted) | -$5.49 | -$0.86 | -$5.46 | -$9.71 | -$7.11 | -$5.15 | -$8.03 | -$5.80 | $2.34 | -$7.13 |
| Shares Outstanding (Diluted) | 48.7 M | 58.8 M | 66.2 M | 73.6 M | 78.0 M | 81.3 M | 87.6 M | 92.4 M | 107.9 M | 104.8 M |
Price
| Price | $18.99 (closing price, November 4, 2026) |
| Market Cap | $2.0B |
| Exchange | NASDAQ |
| Country | US |
Related companies: ALNY · IONS · PTCT · DYN
Explore sector: Healthcare · Biotechnology
More sections of SRPT: Overview · Financials · Valuation · Technical · Ownership
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks